By: Staff Reporter From: precisiononcologynews.com CytoDyn said on Friday that it received Institutional Review Board approval to begin its Phase II basket trial for its CCR5 antagonist leronlimab (PRO 140). The Phase II trial will investigate the drug in 22 different solid tumors. The trial will enroll up to 30 patients who are CCR5 positive. The single-arm study is examining …
CytoDyn Treats First Patient in Phase 1b/2 Clinical Trial with Leronlimab (PRO 140) for Patients with Treatment-Naïve, Metastatic Triple-Negative Breast Cancer
From: globenewswire.com CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications announced today the injection of the first patient in a Phase 1b/2 clinical protocol with treatment-naïve metastatic triple-negative breast cancer (mTNBC). The treatment of the first patient in mTNBC with leronlimab …